Aux Etats-Unis on commence ces jours-ci l’injection de boosters visant BA.4/BA.5, malgré l’absence de données humaines. En Europe l’autorisation viendra peut-être plus tard, pour l’instant on autorise les boosters visant BA.1, qui eux bénéficient d’essais humains.
First adapted COVID-19 booster vaccines recommended for approval in the EU
▻https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu
EMA’s human medicines committee (CHMP) has recommended authorising two vaccines adapted to provide broader protection against COVID-19. Comirnaty [#Pfizer/BioNTech] Original/Omicron BA.1 and Spikevax [#Moderna] bivalent Original/Omicron BA.1 are for use in people aged 12 years and above who have received at least primary vaccination against COVID-19.
[...] Other adapted vaccines incorporating different variants, such as the Omicron subvariants BA.4 and BA.5, are currently under review by EMA or will be submitted soon, and, if authorised, will further extend the arsenal of available vaccines. The clinical data generated with the original/BA.1 bivalent vaccines recommended today will support the evaluation and authorisation of further adapted vaccines.
CDC recommends updated Covid-19 boosters
▻https://www.statnews.com/2022/09/01/cdc-advisory-panel-backs-updated-covid-19-boosters
The updated vaccine is designed to teach the immune system to recognize a broader array of SARS-2 strains by including a second target, the Omicron subvariants BA.4 and BA.5. (The spike protein on viruses from those two subvariants is identical.) BA.5 is currently the dominant virus circulating in the United States.
The new shots can only be used as a booster for people who have had a primary series of vaccines. It is not authorized for use as a primary series.
With the authorization of these boosters, the FDA suspended the authorizations for the previous boosters produced by Pfizer and Moderna. Those monovalent (one strain) boosters can no longer be given in this country, except in children who are too young to receive one of the bivalent boosters.